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Abstract
To date, four main mechanisms mediating inhibition of influenza infection by anti-hemagglu-
tinin antibodies have been reported. Anti-globular-head-domain antibodies block either
influenza virus receptor binding to the host cell or progeny virion release from the host cell.
Anti-stem region antibodies hinder the membrane fusion process or induce antibody-depen-
dent cytotoxicity to infected cells. In this study we identified a human monoclonal IgG1 anti-
body (CT302), which does not inhibit both the receptor binding and the membrane fusion
process but efficiently reduced the nucleus entry of viral nucleoprotein suggesting a novel
inhibition mechanism of viral infection by antibody. This antibody binds to the subtype-H3
hemagglutinin globular head domain of group-2 influenza viruses circulating throughout the
population between 1997 and 2007.
Introduction
Influenza virus is an enveloped RNA virus with two major surface integral-membrane glyco-
proteins, hemagglutinin (HA) and neuraminidase (NA). Membrane-envelope HA consists of
two disulfide-linked glycosylated polypeptides, HA1 and HA2 [1]. The major part of HA1
forms the globular head domain and binds to sialic acid receptors on the host cell plasma mem-
brane; whereas, HA2 forms most of the HA stem region and induces pH-triggered membrane
fusion between the influenza-virus envelope and host-cell endosomal membranes [2]. The
NA protein is crucial for destroying sialic acid-containing receptors on the host cell and viral
membranes, permitting progeny virion release from infected cells [3]. Currently, 17 HA and
10 NA subtypes have been identified, and strains of influenza A virus are classified by subtype
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according to their surface glycoproteins [1, 2]. Three HA subtypes (H1, H2, and H3) and two
NA subtypes (N1 and N2) have caused extensive influenza outbreaks in humans [4]; in particu-
lar, H1N1 and H3N2 influenza viruses are the main causes of seasonal influenza outbreaks [5].
Neutralizing antibodies play a critical role in protecting the host cell from influenza virus
infection. The presence of host-cell antibodies against either HA or NA reduces influenza virus
infectivity [6–11]. The HA globular head domain is the major antigenic component on the
influenza virus surface. Anti-HA antibodies can neutralize the influenza virus by preventing
either of HA’s two functions, i.e., mediating influenza virus attachment to, and membrane
fusion with, the host cell [12]. The presence of anti-HA globular-head-domain antibodies
drives the outgrowth of antigenic variants, resulting in a continuum of changes in HA structure
in viral progeny, known as antigenic drift [13]. Diversity of HA sequences of influenza A virus
is high. There are 17 HA serotypes belonging to one of two major categories: group 1 (H1, H2,
H5, H6, H8, H9, H11, H12, H13, H16, and H17) or group 2 (H3, H4, H7, H10, H14, and H15)
[14].
A minor portion of anti-HA antibodies target the HA stem region, and some of these anti-
bodies can neutralize the influenza virus by inhibiting membrane fusion [13, 15]. Because the
stem region is highly conserved among influenza viruses, antibodies reacting with the HA stem
region tend to be broadly neutralizing against viral infectivity [16].
In this study, we constructed a phage-display combinational antibody library using B cells
obtained from influenza-vaccinated volunteers. From this library, we selected neutralizing
anti-H3 antibodies, one of which neutralized only H3N2 viruses collected between 1997 and
2007, indicating its binding is vulnerable to antigenic drift. Altering seven residues in the
H3N2 HA globular head domain of strains isolated in 1997 to match sequences of strains iso-
lated in 1995 abolished our selected antibody’s reactivity. These observations suggested that the
binding site of this antibody is localized in the HA globular head domain. Interestingly, this
antibody inhibits neither the receptor binding nor the membrane fusion process. But the anti-
body efficiently reduced the nucleus entry of viral nucleoprotein. To the limit of our knowl-
edge, this is the first report on an antibody with a novel inhibitory mechanism of influenza
virus infection not reported hitherto.
Materials and Methods
Ethics Statement
The mouse studies conducted at CDC were performed in accordance to protocols approved by
the Institutional Biosafety Committee and Animal Care and Use Committee (Protocol #2069).
Mice were anesthetized by inhalation of 5% isoflurane/95% O2 before the virus infection to
minimize suffering and monitored daily for clinical signs and body weight recordings (S1
ARRIVE Checklist). Animals that exhibited mild or moderate clinical signs were observed
twice per day, whereas animals that exhibited severe clinical illness were humanely euthanized.
Animals whose body weight reached 75% or less of their initial weight were humanely eutha-
nized immediately. All mice that reached the pre-established euthanasia endpoint were eutha-
nized by an overdose of anesthetic (isoflurane).
All ferret research procedures were reviewed and approved by the IACUC of Bioleaders
(#BLS-ABSL-10-021). Ferrets were monitored daily for clinical signs of infection. Furthermore,
all infections as well as sample collections including blood and nasal rinsed solution were per-
formed under zoletil/xylazine cocktail anesthesia, minimizing animal suffering. For the collec-
tion of lung tissue, ferrets were humanely euthanized by an overdose of anesthetic (zoletil/
xylazine).
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Library construction and biopanning
Total RNA was prepared using TRI Reagent1 (Molecular Research Center, Inc., Cincinnati,
OH, USA) from the peripheral blood mononuclear cells of 13 volunteers who had been vacci-
nated against the A/Uruguay/716/2007 H3N2 strain. All subjects provided the written
informed consent to participate in this study. The protocol was approved by the institutional
Review Board, Gangnam Severance Hospital Yonsei University College of Medicine, Seoul,
Korea (Permit #4-2009-0683) and the study was carried out in strict accordance with the ethi-
cal guidelines of Gangnam severance hospital.
First-strand cDNA was synthesized using SuperScriptTM reverse transcriptase with oligo
(dT) priming (Invitrogen, Grand Island, NY, USA). Using this cDNA, a phage-display library
of human single-chain variable fragments (scFv) was constructed using the pComb3XSS pha-
gemid vector as previously described [17]. Four rounds of panning were performed to select
scFv clones from the library [17]. For each round of biopanning, 1.5 μg recombinant His-
tagged trimeric HA protein from the A/Brisbane/10/2007 strain (Influenza Reagent Resource,
Manassas, VA, USA) was used to coat 5×106 magnetic beads (Dynabeads M-270 epoxy) (Invi-
trogen) used for scFv retrieval.
Enzyme immunoassay
Production and purification of CT302 IgG1 were performed as described previously [18].
Recombinant His-tagged trimeric HA protein from the A/Brisbane/10/2007 strain (5, 10, 50,
100, or 200 ng) dissolved in 20 μl phosphate-buffered saline (PBS) was added to microtiter
plate wells and incubated at 4°C overnight. Plates were washed three times with PBST (PBS
containing 0.05% v/v Tween 20) and incubated for 1 hr at 37°C with 3% (w/v) bovine serum
albumin (BSA) in PBS to block nonspecific antibody binding. After washing plates with PBST,
50 ng CT302 IgG1 or control human anti-respiratory syncytial virus IgG1 (palivizumab) (Med-
Immune Inc., Gaithersburg, MD, USA) was dissolved in 50 μl 3% (w/v) BSA in PBS and added
to each well. After incubation for 1 hr at 37°C, followed by two washes with PBST, plates were
incubated with a commercially available horseradish peroxidase (HRP)-conjugated anti-
human IgG1 solution (Thermo Fisher Scientific, Waltham, MA, USA) diluted 5,000-fold in 3%
BSA in PBS. After washing with PBST, 50 μl HRP colorimetric substrate solution (ABTS)
(Amresco Inc., Solon, OH, USA) was added to each well, and optical density was measured at
405 nm with a microtiter-plate reader (Labsystems S.L., Barcelona, Spain).
Immunoblot analysis
One microgram recombinant His-tagged trimeric HA proteins from H1, H3, and H5 strains
(Influenza Reagent Resource) were dissolved and boiled in Laemmli sample buffer without
2-mercaptoethanol, electrophoresed on 4–12% (w/v) Tris-glycine gradient gels (Novex1
NuPAGE1) (Invitrogen), and transferred to two different nitrocellulose membranes. Mem-
branes were blocked with Tris-buffered saline containing Tween 20 (TTBS: 10 mM Tris/HCl,
pH 7.5; 150 mMNaCl; and 0.05% v/v Tween 20) and 5% (w/v) skim milk (TTBS-M) at room
temperature for 30 min. One membrane was probed with 10 μg/ml CT302 IgG1 in TTBS-M at
room temperature for 2 hr. The membrane was washed with TTBS and incubated at room tem-
perature for 1 hr with HRP-conjugated anti-human IgG (Thermo Fisher Scientific) diluted
5,000-fold in TTBS-M. The other membrane was blocked and incubated at room temperature
for 1 hr with HRP-conjugated rabbit anti-His IgG (Pierce, Rockford, IL, USA) diluted
5,000-fold in TTBS-M. Both membranes were washed three times with TTBS, and protein
bands were visualized using SuperSignal1West Pico Chemiluminescent Substrate (Pierce)
following the manufacturer’s instructions.
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Sequence analysis
Phagemid DNA of selected clones identified by enzyme immunoassays was prepared with a
small-scale plasmid preparation kit (Qiagen, Hilden, Germany). Sequence analysis of positive
clones was performed as previously described [17]. Briefly, the OmpSeq primer (5'-AAGACA
GCTATCGCGATTGCAG-3') was used to sequence the VH and VL chains of the CT302 IgG1
[17], and Accelrys Gene software (Accelrys Inc.; San Diego, CA, USA) was used to search for
homologs of selected clones.
Real-time interaction analysis
Kinetic interactions between CT302 IgG1 and recombinant His-tagged trimeric HA protein of
A/Brisbane/10/07 or A/Wisconsin/67/2005 strains were determined using the BIAcore™T200
system (GE Healthcare, Uppsala, Sweden) [19]. First, anti-His antibody (Ab Chem, Montreal,
Canada) was dissolved (6 μg/ml) in 10 mM sodium acetate buffer (pH 4.5) and immobilized
on a sensor chip, consisting of a gold surface with covalently attached carboxymethylated dex-
tran (CM5 dextran sensor chip) (GE Healthcare), at a flow rate of 5 μl/min using the Amine
Coupling Kit (GE Healthcare). Then recombinant His-tagged trimeric HA protein was dis-
solved at a final concentration of 12 μg/ml in HEPES-buffered saline containing 0.005% surfac-
tant P20, 3 mM EDTA, and 0.15 M NaCl. Subsequently, recombinant His-tagged trimeric HA
protein was injected for 30 sec at a flow rate of 10 μl/min in order to capture recombinant His-
tagged trimeric HA protein with anti-His antibody. The CT302 IgG1 was dissolved in HEPES-
buffered saline, serially diluted 3-fold over the range from 100 to 1.23 nM, and injected over
150 sec into the BIAcore system to bind the immobilized recombinant His-tagged trimeric HA
protein on the sensor chip, at a flow rate of 30 μl/min at 25°C. Dissociation of CT302 IgG1
from the immobilized recombinant His-tagged trimeric HA protein was monitored after the
end of the association phase at a flow-rate of 30 μl/min. The sensor chip surface was regener-
ated with 10 mM glycine (pH 2.0). Evaluation software for BIAcore T-200 version 1.0 (GE
Healthcare) was used to calculate Kon and Koff constants. The BIAcore system was also used to
confirm if there was any competition between CT302 IgG1 and CT149 IgG1 (an anti-HA stem-
region IgG1, unpublished results) in binding to HA protein from the A/Brisbane/10/2007
strain. By immobilizing anti-His antibody on a sensor chip, recombinant His-tagged trimeric
HA protein from A/Brisbane/10/2007 strain was allowed to interact with the anti-His antibody.
Next, either CT302 IgG1 or CT149 IgG1 (diluted to 100 nM) was injected across the surface to
observe the interaction between recombinant His-tagged trimeric HA protein from A/Bris-
bane/10/2007 strain and CT302 IgG1 or CT149 IgG1. The amount of test material bound to the
sensor chip surface in the real-time interaction experiments was expressed in arbitrary reso-
nance units (RU). One RU represents approximately 1 pg protein/mm2 of the sensor chip sur-
face [20].
Microneutralization assay
The microneutralization assay was performed as previously reported using purified CT302
IgG1 with a minor modification [21–23]. Briefly, this assay tests an antibody’s ability to inhibit
influenza virus infection of Madin-Darby canine kidney (MDCK-L) cells in vitro [24]. Influ-
enza viral strains A/Hong Kong/1968, A/Beijing/353/1989-X109, A/Beijing/32/1992-R, A/
Johannesburg/33/1994-R, A/Nanchang/933/1995, A/Sydney/5/1997, A/Panama/2007/1999,
A/Wyoming/3/2003.rg, and A/Brisbane/10/2007 were employed for the assay. Handling of
influenza virus was performed in a biosafety level-2 containment laboratory.
Two-fold serial dilutions of CT302 IgG1 in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 0.3% w/v BSA (Life Technologies), penicillin and streptomycin, and
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25 mMHEPES were mixed with 100 TCID50 of influenza virus in 96-well Costar plates and
incubated for 1 hr at 37°C. During this incubation, plates were shaken at 20-min intervals to
ensure resuspension. The TCID50 value denotes the tissue-culture infective dose required to
cause cytopathic effects in 50% of inoculated cells. MDCK-L cells (3×104/well) were then
added in the presence of 1 μg/ml trypsin (TPCK-trypsin) (Sigma-Aldrich; St. Louis, MO,
USA), and plates were incubated at 37°C under 5% CO2 for 20 hr. After incubation, culture
supernatants were removed, cells were fixed with 80% (v/v) cold acetone in PBS, and plates
were processed for detection of viral proteins with a cell-based ELISA system. A biotin-labeled
monoclonal antibody specific for influenza A virus (Millipore Corp.; Billerica, MA, USA) was
added to each well (100 μl of a 1:2,000 dilution in 1% w/v BSA containing PBST) and incubated
for 1 hr at room temperature. Plates were washed with PBST, and streptavidin-HRP conjugate
(Millipore) was added (100 μl of a 1:15,000 dilution in 1% w/v BSA containing PBST) to each
well. After 1 hr incubation at room temperature, plates were washed and developed with 100 μl
O-phenylenediamine chromogenic substrate for 10 min. The reaction was stopped with 50 μl
of 3N HCl, and the absorbance was measured at 490 nm using a microtiter-plate reader (Lab-
systems S.L.). The microneutralization titer was determined according to previously described
methods [25].
Hemagglutination inhibition assay
The hemagglutination inhibition assay was performed as previously described [26]. Briefly,
20 μg/ml purified CT302 IgG1 was serially diluted 2-fold in PBS and combined with 8 hemag-
glutination units of influenza virus in 96-well cell culture plates. Four strains of influenza virus
were tested: A/Brisbane/10/2007, A/Sydney/5/1997, A/Philippines/2/1982, and A/Hong Kong/
1968. The influenza viruses were propagated in 10-day-old embryonated chicken eggs. After a
1-hr preincubation of antibody with influenza virus, chicken red blood cells (RBCs) were
added to a final concentration of 0.5%, the plate was incubated for 1 hr at room temperature,
and hemagglutination was evaluated by light microscopy.
Cell fusion assay
The cell fusion assay was performed as previously described [13]. Briefly, Chinese hamster
ovary (CHO) cells (Invitrogen) that overexpress HA protein from A/Brisbane/10/2007 strain
were plated at approximately 90% confluence in six-well plates. After incubation at 37°C for
24 hr in DMEM with 10% (v/v) fetal bovine serum (FBS), cells were washed with serum-free
DMEM and incubated for 30 min. Cells were washed with serum-free DMEM again and incu-
bated with 5 μg/ml tolylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin in serum-
free DMEM for 5 min. Subsequently, trypsin was neutralized by adding FBS to a final concen-
tration of 10%. Cells were incubated for 30 min with 10 μg/ml CT302 IgG1, washed with PBS,
and incubated with low-pH fusion-inducing buffer (150 mMNaCl buffered to pH 5.0 with 10
mMHEPES). Cells were returned to DMEM with 10% FBS and incubated 2–3 hr at 37°C.
Finally, cells were fixed with ice-cold methanol and stained with trypan blue.
Viral entry assay
Entry fusion (EF) and nuclear import (EI) assay were carried out as previously described [27,
28]. In the EF assay, membrane fusion between the virus envelope and endosomal membrane
was observed using A/Brisbane/10/2007 virus labeled with the lipophilic fluorescent dyes R18
and SP-DiOC18 (Molecular Probes/ Thermo Fisher Scientific, MA, USA). Then labeled viruses
were pre-incubated with 12.5 mg/ml CT302 IgG1 or anti-respiratory syncytial virus IgG1 (pali-
vizumab) (MedImmune Inc.) at 37 °C for 30 min. A549 cells grown to 50% confluence in
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96-well μ clear-plate, black were inoculated with R18/DiOC18-labeled and antibody pre-incu-
bated A/Brisbane/10/2007 virus (MOI of 3.5) at 4°C for 1 h. After virus adsorption, cells were
washed with ice-cold PBS three times, and then incubated at 37°C for 2 hr. For the control,
cells were treated with 100 nM Bafilomycin A1 (Sigma Aldrich, USA) that inhibits the endoso-
mal acidification thereby blocks the membrane fusion of the virus.
In the EI assay, A/Brisbane/10/2007 virus was pre-incubated with CT302 IgG1, palivizumab
or treated with Bafilomycin A1. Then the virus was used to infect A 549 cells. After virus
adsorption, cells were washed with ice-cold PBS three times, and then incubated at 37°C. At 9
hr post infection, cells were fixed with 4% PFA and permeabilized with 0.25% Triton X-100.
Viral nucleoprotein (NP) that is trans-located into the nucleus was stained by mouse monoclo-
nal anti-influenza A virus nucleoprotein antibody [AA5H] (cat # ab20343, Abcam, UK). All
images were acquired by Opera (PerkinElmer, MS, USA) (20x).
Protection of mice from influenza virus infection by CT302 IgG1
Eight-week-old female BALB/c mice were purchased from Jackson Labs (Bar Harbor, ME,
USA). Five mice of each group (described below) were anesthetized and infected via intranasal
delivery with strain A/NYMC X-171 or A/Hong Kong/1/1968 (50 μl containing 1.47 x 102 pfu-
doses). The A/NYMC X-171 (50 μl containing 3.2 x 105 EID50-doses) is a mouse-adapted
PR8-reassortant influenza virus with surface genes from A/Brisbane/10/2007 strain [29]. Mice
received 2 mg/kg or 10 mg/kg of CT302 IgG1 by intraperitoneal injection either 24 hr before,
24 hr after, or 48 hr after viral challenge. The antibody was diluted with 0.9% (w/v) saline solu-
tion, and PBS was used as a negative control. Mice were observed twice a day for up to 14 days,
at which times the weight, clinical score, and survival were noted. Survival rates were compared
among groups by using the log-rank test using GraphPad Prism (version 6.0) software. Differ-
ences were considered statistically significant when p<0.05.
Protection of ferrets from influenza virus infection by CT302 IgG1
Sixteen-week-old castrated male ferrets (Mustela putorius furo) were purchased from Triple F
Farms (Sayre, PA, USA) and housed in a pathogen-free environment for 7 days prior to infec-
tion with A/Brisbane/10/2007 strain. Upon receipt, ferrets were grouped during the acclima-
tion period based on body weight in order to yield groups with approximately equal mean
body weight. Before the infection, blood was collected from the ferrets and tested using the
hemagglutinin inhibition (HI) assay to identify potential previous infection with influenza
virus as described previously [30].
Nine ferrets of each group (see below) were infected intranasally with 1×106 TCID50 units
of A/Brisbane/10/2007 strain. TCID50 was defined as the tissue-culture infective dose required
to cause cytopathic effects in 50% of inoculated cells. At day 1 post-infection, the infected fer-
rets were intravenously injected either with CT302 IgG1 (30 mg/kg) or an equal amount of
anti-respiratory syncytial virus IgG1 (palivizumab) (MedImmune Inc.) as isotype-matched
negative control antibody. Ferrets were monitored daily for up to 9 days post-infection. On
days 1, 3, 5, and 9 after infection, 1 ml PBS containing penicillin and streptomycin was used as
a nasal rinse solution to evaluate viral titers in the nasal cavity. Two ferrets from each group
were randomly euthanized for lung tissue collection on days 1, 3, and 9, and three ferrets were
sacrificed on day 5. Lung tissues of ferrets were mechanically homogenized in PBS containing
penicillin and streptomycin using a TissueLyser (Qiagen), and homogenates were centrifuged
at 13,000×g for 10 min to clarify supernatants. Supernatants were recentrifuged two times to
assure separation from visible lung-tissue remnants. Infectious viral titers of the supernatants
were determined using a TCID50 assay [30]. Statistical significance was assessed by paired
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Student's t-tests using SigmaPlot 10.0 (SPSS; Chicago, IL, USA), with p<0.05 as level of statisti-
cal significance.
Flow cytometry
DNA fragments encoding either wild-type HA protein of A/Brisbane/10/2007 strain or A/Nan-
chang/933/1995-like mutants (E62K, N121T, S124G, N133D, K158E, A196V, and K276N)
were chemically synthesized and ligated into pCEP4 vectors, which were transfected into
human embryonic kidney (HEK293T, Invitrogen) cells as described previously [31, 32]. After
24 hr, 10 μg/ml test antibodies dissolved in flow cytometry buffer (PBS containing 1% w/v BSA
and 0.05% w/v sodium azide) were incubated with transfected cells at 37°C for 1 hr. CT149
IgG1 was used as a positive control, and anti-respiratory syncytial virus IgG1 (palivizumab)
(MedImmune Inc.) served as a negative control. After centrifugation at 1,000×g for 10 min,
cells were washed twice with PBS. Cells were then incubated for 1 hr at 37°C with FITC-labeled
anti-human IgG (Thermo Fisher Scientific), diluted 100-fold in flow cytometry buffer, and
analyzed by flow cytometry using a FACSCanto™ II instrument (BD Biosciences; San Jose, CA,
USA) equipped with a 488-nm laser. Ten thousand cells were detected per measurement with
no gating, and results were analyzed using FlowJo software (TreeStar Inc.; Ashland, OR, USA).
Visualization of HA three-dimensional surface structure
The three-dimensional structure of H3N2 HA was generated by molecular visualization system
software PyMOL 1.3 (http://www.pymol.org).
Results
Generation of monoclonal antibodies against influenza virus H3N2
Thirteen healthy volunteers who had not been vaccinated against influenza virus within the
previous 2 years were vaccinated against the A/Uruguay/716/2007 (H3N2) strain. Almost all of
the donor sera showed increased antibody titers after vaccination (data not shown). Using
mRNA from mononuclear cells of the vaccinated group, we generated a scFv library with a
complexity of 1.65×1010 clones. Next, we performed four rounds of biopanning and enzyme
immunoassay to select phage bound to recombinant trimeric HA protein of the A/Brisbane/
10/2007 strain, which shares the same amino acid sequence (except A138) with A/Uruguay/
716/2007 (accession number CY121632.1). Twenty positive clones were identified among 192
colonies initially tested, and sequence analysis revealed 14 positive clones with unique amino-
acid sequences. From these 14 positive clones, we selected the five most reactive clones to gen-
erate human anti-HA IgG1 antibodies. Reactivity of the antibodies to HA was confirmed by
enzyme immunoassay and immunoblot analysis (Fig 1A and 1B, respectively).
The microneutralization assay was used to test the neutralizing activity of these five anti-
HA IgGs against H3N2 influenza virus. We tested three H3N2 influenza viruses: A/Brisbane/
10/2007, A/Hong Kong/1968, and A/Puerto Rico/8/1934 strains. All five antibody clones effi-
ciently neutralized only the A/Brisbane/10/2007 strain, and we selected the three antibodies
with the greatest neutralization activity. Among these three antibody clones, we selected
CT302 IgG1 for further studies because it expressed the highest yield. The amino-acid
sequences of the VH and VL variable regions of CT302 IgG1 are shown in Fig 1C. In real-time
interaction analysis of CT302 IgG1, using HA-coated chips (recombinant His-tagged trimeric
HA from A/Brisbane/10/2007 and A/Wisconsin/67/2005 strains), we determined that the KD
constants were 6.06±0.03×10−10 and 8.55±0.74×10−9, respectively (Table 1).
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In vitro neutralizing and blocking activity of CT302 IgG1 against diverse
influenza A strains
To determine the neutralizing activity of CT302 IgG1 against a spectrum of seasonal H3N2
viruses circulating during the past decade, we performed additional microneutralization assays
with nine different H3N2 viruses isolated between 1968 and 2007. CT302 IgG1 neutralized sev-
eral recently identified H3N2 subtypes of influenza A viruses: A/Brisbane/10/2007, A/Wyo-
ming/3/2003.rg, A/Panama/2007/1999, and A/Sydney/5/1997 strains (Table 2). Interestingly,
CT302 IgG1 did not neutralize H3N2 strains identified during or before 1995, such as A/Nan-
chang/933/95, A/Johannesburg/33/1994-R, A/Beijing/32/1992-R, A/Beijing/353/1989-X109, or
A/Hong Kong/1968 strains.
Next, we performed a hemagglutination inhibition assay to assess potential CT302 IgG1
inhibition of viral attachment to the sialic-acid receptor on the surface of target cells, and we
performed a membrane-fusion assay to investigate CT302 IgG1’s potential inhibition of influ-
enza virus HA-induced target-cell membrane fusion. The hemagglutination inhibition assay
Fig 1. Reactivity of CT302 IgG1 to H3N2 trimeric HA. (A) After recombinant trimeric HA protein was coated onto 96-well plates, CT302 IgG1 (&) or
negative-control anti-respiratory syncytial virus IgG1 (&) was incubated in wells as primary detection antibodies. Antibody bound to the recombinant His-
tagged trimeric HA protein was detected with an HRP-conjugated anti-human IgG by addition of HRP substrate. Results represent the mean±S.D. obtained
from duplicate wells per each condition. (B) Recombinant His-tagged trimeric HA proteins from H1, H3, and H5 strains were resolved by SDS-PAGE and
transferred to nitrocellulose membranes, which were probed with CT302 IgG1 or anti-His antibody. (C) Amino acid sequences in the VH and VL regions of
CT302 IgG1. HA, hemagglutinin; HRP, horseradish peroxidase.
doi:10.1371/journal.pone.0141312.g001
Table 1. Affinity constants (Ka, Kd) of CT302 IgG1 determined by real-time interaction analysis.
Immobilized HA protein KD (M) Ka (M-1S-1) Kd (S-1)
A/Brisbane/10/2007 6.06±0.03×10−10 2.93±0.03×105 1.78±0.01×10−4
A/Wisconsin/67/2005 8.55±0.74×10−9 2.91±0.07×105 2.45±0.15×10−3
Ka, association rate constant; Kd, dissociation rate constant; KD, dissociation equilibrium constant calculated based on Kd/Ka; M, molarity.
doi:10.1371/journal.pone.0141312.t001
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utilized chicken RBCs to test CT302 IgG1 against four influenza virus strains: A/Brisbane/10/
2007, A/Sydney/5/1997, A/Philippines/2/1982, and A/Hong Kong/1968 strains. Even at the
highest concentration tested (20 μg/ml), CT302 IgG1 did not show any hemagglutination-
inhibitory activity against any of the influenza strains tested (Fig 2A), while a control antibody
effectively inhibited hemagglutination in a parallel experiment (data not shown). In the
absence of the influenza virus, CT302 IgG1 did not induce the hemagglutination of chicken or
turkey RBCs (data not shown).
In the cell-membrane fusion assay using CHO cells that overexpressed HA protein from A/
Brisbane/10/2007 strain, CT302 IgG1 at a concentration of 10 μg/ml completely inhibited HA-
dependent CHO-cell membrane fusion (Fig 2B). In viral entry fusion (EF) assay, CT302 IgG1
at the concentration of 12.5 mg/ml did not block fusion of viral and vacuolar membranes of
cells (Fig 3), which is contradictory to the result of the cell-based membrane fusion assay in
this study.
To monitor the traffic of viral NP to nucleus, we followed the nuclear accumulation of NP
using NP monoclonal antibody in the EI assay. In this assay we found the nuclear accumula-
tion of viral NP in the cells treated with CT302 IgG1 was lower than that of NP in the cells
treated with the control IgG1 (Fig 3).
In vivo neutralizing activity of CT302 IgG1 on influenza infectivity
The preventive potential of CT302 IgG1 against influenza virus infection was tested in mice
using the A/NYMC X-171 strain (mouse-adapted A/Brisbane/10/2007 strain) and A/Hong
Kong/1/1968. Influenza infection in PBS-treated control mice resulted in only 20% survival
after 9 days, which was consistent throughout the 14-day experiment. All mice pretreated
before influenza virus infection with CT302 IgG1, at either 2 or 10 mg/kg, survived through the
two-week observation period. This demonstrates that CT302 IgG1 has a potent preventative
effect against infection by strain A/NYMC X-171 (p<0.05; hazard ratio, 0.08; 95% confidence
interval, 0.01–0.59). To explore the therapeutic potential of CT302 IgG1, mice were first inocu-
lated with influenza virus and then treated with CT302 IgG1. After administering 10 mg/kg
CT302 IgG1 at 24 or 48 hr postinfection, mouse survival rates were 80% (p = 0.08) or 60%
(p = 0.28), respectively, at 14 days postinfection. When mice were treated either 24 or 48 hr
postinfection with 2 mg/kg CT302 IgG1, the survival rates were 40% (p = 0.08 and 0.06,
Table 2. Microneutralization activity of CT302 IgG1 against influenza virus strains.










aMN (microneutralization) titers are expressed as the lowest concentration of purified CT302 IgG1 that
completely neutralized the influenza virus.
bNo detectable neutralization activity at the concentration of 20 μg/ml.
doi:10.1371/journal.pone.0141312.t002
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respectively) (Fig 4A. a). In correlation with microneutralization result, CT302 IgG1 did not
show any prophylactic or therapeutic efficacy in mice infected with A/Hong Kong/1/1968 (Fig
4A.b).
To evaluate the efficacy of CT302 IgG1 in suppressing viral replication, ferrets were first
infected with A/Brisbane/10/2007 strain and then treated intravenously on day 1 postinfection
with either CT302 IgG1 or control anti-respiratory syncytial virus IgG1 (30 mg/kg) (Fig 4B).
The nasal-cavity viral titers of infected ferrets treated with CT302 IgG1 were significantly lower
on days 3 and 5 postinfection than in ferrets treated with control anti-respiratory syncytial
virus IgG1 (p<0.05 at both time points). The viral titers in lung tissue were also significantly
lower at day 5 postinfection in CT302 IgG1-treated ferrets than in animals treated with control
anti-respiratory syncytial virus IgG1 (p<0.05).
Fig 2. Inhibition of hemagglutination and cell fusion by CT302 IgG1. (A) Two-fold dilutions of CT302 IgG1 (over the range of 20 to 0.039 μg/ml in PBS)
were added to wells harboring 8 hemagglutination units of influenza virus, and chicken red blood cells (RBCs) were added to a final concentration of 0.5%.
Control A wells contained only RBCs and influenza virus, without CT302 IgG1. Control B wells contained only RBCs, without influenza virus or CT302 IgG1.
(B) CHO cells expressing HA protein of A/Brisbane/10/2007 strain were incubated with CT302 IgG1 and then exposed to low-pH medium (pH 5.0) to induce
membrane fusion. As controls, cells not treated with CT302 IgG1 but exposed to low pH, or cells not treated with CT302 IgG1 and not exposed to low pH, are
shown. Magnification: 40×, 100×. TCID50, tissue-culture infective dose required to cause cytopathic effects on 50% of inoculated cells.
doi:10.1371/journal.pone.0141312.g002
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Epitope mapping of CT302 IgG1
Amino-acid residues that differed between viral strains A/Sydney/5/1997 (neutralized by
CT302 IgG1) and A/Nanchang/933/1995 (not neutralized by CT302 IgG1) were found at posi-
tions 62 (E or K), 121 (N or T), 124 (S or G), 133 (N or D), 158 (K or E), 196 (A or V), and 276
(K or N) (Fig 5A and 5B).
To determine the effect of amino acid substitutions on the binding of CT302 IgG1 to HA of
the A/Brisbane/10/2007 strain, we expressed six HA mutants on the cell surface of HEK293T
cells. Expression levels of HA mutants were confirmed by flow cytometry using CT149 IgG1,
which targets the HA stem region, and using an isotype-matched human IgG1 antibody as neg-
ative-control (Fig 5C). CT302 IgG1 strongly reacted to HA of A/Brisbane/10/2007 strain
(ENSNKAK) but did not react to the KTGDEVN mutant, whose sequence is exactly homolo-
gous to the HA of the A/Nanchang/933/1995 strain. The CT302 IgG1 showed notably
decreased reactivity to ENSNEVK, ETGDEVK, and ETGDKAK mutants, while minimal or no
decreased reactivity was observed using KNSNKAN and KTGDKAN mutants (Fig 5C). These
data suggest that the 121N, 124S, 133N, 158K, and 196A residues are involved in the interac-
tion between HA and CT302 IgG1.
Fig 3. Effect of CT302 IgG1 on the membrane fusion and the traffic of viral nucleoprotein to nucleus. Entry fusion (EF) assay: Virus particles were
labeled with DiOC18 and R18, and were allowed to enter CT302 IgG1-, Bafilomycin A1- or control IgG1-treated cells. Fusion of viral and vacuolar
membranes of cells triggered dequenching of DiOC18 (green) signal co-localized with the R18 (Red) signal. Nuclear import (EI assay): In the CT302 IgG1-,
BafilomycinA1- or control IgG1-treated cells, virus particles were allowed to enter nucleus. Incoming NP proteins (green) were detected within the nucleus
(blue) by the anti-NP antibody. Magnification: 20×.
doi:10.1371/journal.pone.0141312.g003
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Fig 4. Protective and therapeutic effects of CT302 IgG1 in influenza virus-infected mice and ferrets. (A) CT302 IgG1 was administered intraperitoneally
to mice at -24, +24, or +48 hr from infection with A/NYMC X-171 strain (mouse-adapted A/Brisbane/10/2007 strain) (a, c) or A/Hong kong/1/1968 (b, d), and
survival rate (a, b) and body weight change (c, d) were monitored twice daily up to 14 days. (B) Ferrets were challenged with the influenza virus and treated
intravenously either with 30 mg/kg CT302 IgG1 or control IgG1 after 1 day. Subsequently, viral titers in the nasal fluid and lung tissue were determined.
#p<0.05 (vs. PBS) determined by log-rank (Mantel-Cox) test. *p<0.05 (vs. control) on day 5, determined by Student’s t-test. TCID50, tissue-culture infective
dose required to cause cytopathic effects on 50% of inoculated cells.
doi:10.1371/journal.pone.0141312.g004
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Fig 5. Binding activity of CT302 IgG1 to HAmutants. (A) Globular head domain of HA protein is composed of residues 52 to 277. The amino-acid
sequences for HA protein were downloaded from the Influenza Virus Resource at the National Center for Biotechnology Information (NCBI). The NCBI
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Real-time interaction analysis
Because all differing residues between the two influenza strains that showed strong (A/Sydney/
5/1997 strain) or no reactivity (A/Nanchang/933/1995 strain) to CT302 IgG1 were located in
the HA globular head domain, we assumed the binding site of CT302 IgG1 was localized in the
globular head domain. To confirm this, we determined if CT302 IgG1 could bind to HA in the
presence of another neutralizing antibody, CT149 IgG1, which binds to the HA stem region.
Only two epitopes on the HA stem region related to neutralizing-antibody binding have been
identified, and these epitopes share some overlapping residues [33]. Therefore, if CT302 IgG1
does not compete with CT149 IgG1 for HA binding, we would conclude CT302 IgG1 binds spe-
cifically to the HA globular head domain.
In real-time interaction analysis, recombinant His-tagged HA protein was conjugated to the
sensor chip surface. After conjugation, a sufficient amount of CT302 IgG1 was injected to
completely cover the chip-bound recombinant His-tagged HA protein, which we confirmed by
observing no additional increase in resonance after another injection of CT302 IgG1 (Fig 5D,
left graph). After establishing maximal CT302 IgG1 binding, we injected CT149 IgG1, which
successfully bound to recombinant His-tagged HA protein, indicating that these two antibodies
noncompetitively bind to different HA epitopes. In a parallel experiment, the sequence of
injecting these two antibodies was reversed. CT302 IgG1 successfully bound to chip-immobi-
lized recombinant His-tagged HA that was saturated with CT149 IgG1 (Fig 5D, right graph),
also indicating noncompetitive HA binding by these two antibodies.
Discussion
Four main antiviral mechanisms are known to inhibit influenza infection by monoclonal anti-
bodies that target HA [34]. First, antibodies such as S139/1, CH65, 1F1, and HC63 disrupt
virus attachment to sialic acid residues on the surface of the host cell, thereby blocking viral
entry [35–37]. These antibodies are generally found to inhibit hemagglutination. Second, anti-
HA globular head-domain monoclonal antibodies, such as CR8071 and CR8033, inhibit prog-
eny virion released from infected cells [38], and different antibody-binding epitopes exist
among diverse influenza strains. For example, CR8033 has hemagglutination-inhibitory activ-
ity, blocking target-cell infection by influenza virus when preincubated with the B/Florida/4/
2006 strain, but has no effect on strain B/Malaysia/2506/2004 infectivity. CR8071 does not pre-
vent cell infection by either influenza virus [38]. Third, some anti-HA stem-region monoclonal
antibodies, such as C179, CR6261, F10, and CR8020, interfere with viral membrane fusion to
target cells in cell-based membrane fusion assay [35] without interfering with receptor interac-
tions that mediate virion attachment. Antibodies CR6261 and F10 inhibit HA conformational
changes, while CR8020 inhibits cleavage by trypsin [16]; neither of these antibodies inhibits
hemagglutination. Fourth, several anti-stem antibodies, such as 6F12, F16, 2G02, 2B06, and
1F02, require FcγR interactions to protect the host cell from influenza virus [34]. These anti-
bodies depend on Fc interactions with FcγR to achieve antiviral activity and can mediate anti-
body-dependent cytotoxicity of infected cells.
accession numbers are indicated next to each strain name. (B) Locations of the seven residues (62, 121, 124, 133, 158, 196, and 276) that vary among the
influenza strains that are either neutralized or not neutralized by CT302 IgG1 are indicated in the three-dimensional structure of HA. The illustrations were
constructed on H3N2 HA (Protein Data Bank accession code 4FNK) using molecular-visualization system software PyMOL 1.3. (C) HEK293T cells
expressing wild-type or mutant HA were analyzed by flow cytometry using CT302 IgG1, CT149 IgG1 (an anti-stem-region IgG1), or an anti-respiratory
syncytial virus IgG1 (negative control). (D) In real-time interaction analysis, sensor chips were first conjugated with anti-His antibody. Next, His-tagged
recombinant HA protein of A/Brisbane/10/2007 stain was loaded, and the interaction of HA protein with CT302 IgG1 or CT149 IgG1 was examined by
sequentially applying these antibodies. Either antibody bound after presaturation with the other antibody, indicating that these two antibodies bind
noncompetitively to different epitopes. RU, resonance units.
doi:10.1371/journal.pone.0141312.g005
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The anti-HA globular head-domain antibody CT302 IgG1, explored in our current study,
did not block the membrane fusion between the virus envelope and endosomal membrane as
shown in our EF assay, while it blocked the membrane fusion in cells displaying HA protein in
the cell fusion assay. As the EF assay represent physiologically more relevant condition of influ-
enza virus infection process, we believe that CT302 IgG1 does not block the membrane fusion
process.
On the other hand, the CT302 IgG1 inhibited nuclear import of NP in EI assay. Currently
we do not know the mechanism by which CT302 IgG1 can block the nuclear import of NP. Tri-
partite motif (TRIM)-containing proteins, especially TRIM5α, act to repress viral replication.
TRIM5α has two known functions in the cell. It has a role as a defensive retroviral capsid-bind-
ing protein that can inhibit retroviral infection. The second role is as an E3 ubiquitin ligase that
promotes NF-kB and AP-1 transcription factor signaling [39]. The general accepted model of
TRIM5α restriction is that when bound to capsids, it recruits proteasomes that potentiate
disassembly of the capsid. However, in the absence of the second stage of restriction that is pro-
teasome-dependent, the fate of the non-infectious TRIM5α–capsid complex is uncertain.
Although the viral uncoating is not rapid and the virus has sufficient time and resources to
undergo reverse transcription, it is prevented from entering the nucleus and forming DNA cir-
cles [39, 40]. Similarly, CT302IgG1 prevents NP to nucleus. Although the mechanisms by
which CT302 IgG1 and TRIM5α block nuclear import is not yet clear, it is clear that there is a
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